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Aims The aim of this study was to use human genetics to investigate the pathogenesis of sick sinus syndrome (SSS) and




We performed a genome-wide association study of 6469 SSS cases and 1 000 187 controls from deCODE genetics, the
Copenhagen Hospital Biobank, UK Biobank, and the HUNT study. Variants at six loci associated with SSS, a reported mis-
sense variant in MYH6, known atrial fibrillation (AF)/electrocardiogram variants at PITX2, ZFHX3, TTN/CCDC141, and
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SCN10A and a low-frequency (MAF = 1.1–1.8%) missense variant, p.Gly62Cys in KRT8 encoding the intermediate filament
protein keratin 8. A full genotypic model best described the p.Gly62Cys association (P = 1.6 10-20), with an odds ratio
(OR) of 1.44 for heterozygotes and a disproportionally large OR of 13.99 for homozygotes. All the SSS variants increased
the risk of pacemaker implantation. Their association with AF varied and p.Gly62Cys was the only variant not associating
with any other arrhythmia or cardiovascular disease. We tested 17 exposure phenotypes in polygenic score (PGS) and
Mendelian randomization analyses. Only two associated with the risk of SSS in Mendelian randomization, AF, and lower
heart rate, suggesting causality. Powerful PGS analyses provided convincing evidence against causal associations for body
mass index, cholesterol, triglycerides, and type 2 diabetes (P> 0.05).
...................................................................................................................................................................................................
Conclusion We report the associations of variants at six loci with SSS, including a missense variant in KRT8 that confers high
risk in homozygotes and points to a mechanism specific to SSS development. Mendelian randomization supports a
causal role for AF in the development of SSS.
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Introduction
Sick sinus syndrome (SSS) is a complex cardiac arrhythmia and the
leading indication for permanent pacemaker implantation world-
wide.1 It is characterized by pathological sinus bradycardia, sinoatrial
block, or alternating atrial brady- and tachyarrhythmias. Symptoms in-
clude fatigue, reduced exercise capacity, and syncope.2,3 Few studies
have been conducted on the basic mechanisms of SSS and therapeut-
ic limitations reflect an incomplete understanding of the pathophysi-
ology. No specific treatment option is aimed at underlying pathways
Graphical Abstract
Summary of genetic insight into the pathogenesis of SSS and the role of risk factors in its development. Variants at six loci (named by corresponding gene
names) were identified through GWAS and their unique phenotypic associations provide insight into distinct pathways underlying SSS. Investigation of the
role of risk factors in SSS development supported a causal role for AF and heart rate and provided convincing evidence against causality for BMI, choles-
terol (HDL and non-HDL), triglycerides and T2D. Mendelian randomization did not support causality for CAD, ischaemic stroke, heart failure, PR interval
or QRS duration (not shown in figure). Red and blue arrows represent positive and negative associations, respectively.
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and trying to determine who benefits from cardiac pacing can be chal-
lenging.4 A better understanding of mechanisms leading to SSS is cru-
cial for improvements in treatment and prevention and genetic
studies provide an opportunity to gain such insight.
Coding variants in several genes, including HCN4, SCN5A, and
GNB2, have been implicated in rare familial SSS through linkage ana-
lysis and candidate gene methods.5–15 In the only published genome-
wide association study (GWAS) of SSS to date, we identified a strong
association with a missense variant in MYH6, encoding the alpha-
heavy chain subunit of cardiac myosin. This was the first GWAS dis-
covery implicating a cardiac structural or contractile unit as a primary
cause of arrhythmia.16
Age is the strongest risk factor for SSS,17 potentially reflecting de-
generative fibrosis and electrical remodelling of the SA node and the
atria in general.18–20 SSS often coexists with the more common atrial
fibrillation (AF)21 and the two arrhythmias are thought to predispose
to each other.22 We have previously examined the role of AF in SSS
development through Mendelian randomization,23 a method using
sequence variants associated with a risk factor (AF) as unbiased
proxy indicators to determine whether the risk factor can cause a
disease (SSS).24,25 The study supported causality,23 likely mediated
through atrial remodelling.26,27 Several other traits have been associ-
ated with SSS while the nature of the associations has not been
ascertained. These include body mass index (BMI), height, heart rate,
and cardiovascular diseases such as hypertension, myocardial infarc-
tion, heart failure, and stroke.17
To gain insight into the pathogenesis of SSS, we performed a large
GWAS of over 6000 cases and one million controls of European des-
cent. We used polygenic scores (PGSs) and Mendelian randomization
to determine the nature of the associations of risk factors with SSS
and in particular whether they contribute to the cause of the disease.
Methods
The study design is two-fold (Supplementary material online, Figure S1).
First, we performed a meta-analysis of GWASs, searching for associations
of sequence variants with SSS. In total 6469 SSS cases were compared to
1 000 187 controls in a meta-analysis of material from deCODE genetics
Iceland, the Copenhagen Hospital Biobank Cardiovascular Study (CHB-
CVS)/Danish Blood Donor Study (DBDS), and the UK Biobank,28 with
follow-up in the Norwegian Nord-Trøndelag Health Study (HUNT).29
Second, we performed PGS analysis and Mendelian randomization to
examine the role of putative risk factors in SSS development (for detailed
methods, see Supplementary material online).
Sick sinus syndrome study populations
The deCODE genetics SSS sample consisted of 3577 Icelanders diag-
nosed with SSS and 347 764 controls. The CHB-CVS included 2209 SSS
cases. The control group included blood donors from the DBDS
(N > 99 000)30 and SSS cases were also compared to subjects in CHB-
CVS with other cardiovascular conditions (N > 89 000). The SSS popula-
tion from the UK Biobank consisted of 403 cases and 403 181 controls.28
The HUNT cohort consisted of 280 Norwegian SSS cases and 69 141
controls recruited through a population-based health survey conducted
in the Nord-Trøndelag County, Norway.29 In all four cohorts, SSS diag-
nosis was based on International Classification of Diseases 9th (ICD-9:
427.8) or 10th revision (ICD-10: I49.5) from hospitals and/or outpatient
clinics. The cohorts are described in more detail in Supplementary mater-
ial online, Methods and Supplementary material online, Table S1.
Genotyping
The deCODE study was based on whole-genome sequence data from
28 075 Icelanders participating in various disease projects. The 32.9 mil-
lion variants that passed quality threshold were imputed into 127 175
Icelanders who had been genotyped using Illumina SNP chips. Finally,
genotype probabilities for untyped relatives were calculated based on
Icelandic genealogy.31 Genotyping for CHB-CVS and DBDS was per-
formed at deCODE using a north European sequencing panel of 15 576
individuals (including 8429 Danes) for imputation into those chip typed
(methods manuscript in preparation). Genotyping in the UK Biobank has
been described in detail elsewhere.32–35 Illumina HumanCoreExome
arrays were used for genotyping in the HUNT cohort.
Genome-wide association study: statistical
analysis
We performed a meta-analysis of GWAS of 6189 SSS cases and
931 046 controls from deCODE genetics, CHB-CVS/DBDS, and the UK
Biobank. We then tested genome-wide significant and suggestive variants
(Supplementary material online, Methods) among 280 cases and 69 141
controls from the Norwegian HUNT study. We used logistic regression
to test for association between sequence variants and SSS and other
case–control phenotypes, treating phenotype status as the response and
allele count as a covariate. Other available individual characteristics that
correlate with phenotype status were included in the model as nuisance
variables. SSS associations were tested under additive, recessive, and full
genotypic models. The full genotypic model includes separate parame-
ters for heterozygotes and homozygotes. We corrected the threshold
for genome-wide significance for multiple testing with a weighted
Bonferroni adjustment using as weights the enrichment of variant classes
with predicted functional impact among association signals estimated
from the Icelandic data.36 Significance thresholds were 1.3 10-7 for var-
iants with high impact, 2.6 10-8 for variants with moderate impact
(including missense), 2.4 10-9 for low-impact variants, 1.2 10-9 for
other variants in Dnase I hypersensitivity sites, and 7.5 10-10 for all
other variants.36 We used linear regression to test variant associations
with quantitative phenotypes, treating the quantitative measurement as
response and the genotype as covariate. These included endopheno-
types of SSS, chronotropic response to exercise (N = 7746), and elec-
trocardiogram (ECG) measurements (N  73 000) (see Supplementary
material online, Methods for detail).
Analysis of genetic risk shared by sick sinus
syndrome and putative risk factors
We used PGSs for 17 exposure phenotypes to examine their correl-
ation with SSS (Supplementary material online, Table S2). The pheno-
types were chosen because of reported epidemiological associations
with SSS or other cardiovascular conditions (see Supplementary material
online, Methods). The PGSs were generated using summary statistics
from the largest available GWASs (training sample) for each phenotype
that do not include deCODE data (Supplementary material online, Table
S2 and Supplementary material online, Figure S1). Subsequently, they
were tested for association with the risk of SSS among 2556 chip-typed
individuals from deCODE (target sample). P-values were corrected using
genomic control.37
The use of PGSs to detect association between exposure and out-
come is a robust method such that the absence of association in a well-
powered PGS analysis provides strong evidence against causality.25
However, finding association in PGS analysis does not confirm causal-
ity.38,39 For the eight PGSs that associated with SSS, we performed a
2-sample Mendelian randomization analysis, equivalent to a fixed effect































































































MR-Egger40 using published genome-wide significant SNPs from the larg-
est available GWAS on each exposure phenotype as genetic instru-
ments.41–49 To estimate the causal effect, we regressed the published
effects of the SNPs on the respective exposure phenotype against their
SSS effects in deCODE, CHB-CVS/DBDS, and the UK Biobank, using
minor allele frequency (MAF) (1 - MAF) as weights. For the ECG meas-
urements PR interval and QRS duration, effects in milliseconds were con-
verted to standard deviations (SDs) according to one SD in the Icelandic
data so that all causal estimates in a Mendelian randomization forest plot
correspond to equal odds ratio (OR) or SD changes for binary and quan-
titative traits, respectively. For significant associations, we performed fur-
ther sensitivity analysis to detect outliers (funnel plots) and tested for
directional pleiotropy using the MR-Egger intercept test (see
Supplementary Material online, Methods).40
Results
Six sick sinus syndrome loci
In a GWAS comparing 6469 SSS cases to 1 000 187 controls, variants
at six loci satisfied our criteria for genome-wide significance (Table 1,
Supplementary material online, Table S3, Figure 1, and Supplementary
material online, Figure S2), with ORs ranging from 1.12 to 8.88. One is
at a novel SSS locus, a low-frequency missense variant, p.Gly62Cys
(MAF = 1.1–1.8% in the four cohorts) in the gene KRT8 on chromo-
some 12. This variant has not been associated with arrhythmias or
ECG traits before. The other variants are the rare Icelandic SSS mis-
sense variant p.Arg721Trp in the sarcomere gene MYH6,16 common
variants at two AF loci, PITX250 and ZFHX3,51 and two ECG loci,
TTN/CCDC14152 and SCN10A.52–54 We have previously reported sec-
ondary associations of variants at the four AF and ECG loci with
SSS.23,52 At the TTN/CCDC141 locus, we report associations of two
missense variants, p.Thr811Ile in TTN and p.Glu382Asp in CCDC141,
that are weakly correlated (R2 = 0.20, D’ = 0.64, Supplementary ma-
terial online, Table S4).
High penetrance of sick sinus syndrome
among homozygotes for p.Gly62Cys in
KRT8
The SSS association of p.Gly62Cys in KRT8 was discovered with the
additive model (Table 1 and Supplementary material online, Tables S5
and S6). However, homozygotes of p.Gly62Cys have a higher risk of
SSS than assumed under the additive model (Table 2, homozygous
genotypic OR > 1.622 = 2.62, Pfull vs. additive = 2.1 10-8). We
observed an OR of 1.44 for heterozygotes (95% CI = 1.26–1.65) and
13.99 for homozygotes (95% CI = 8.16–23.98), compared to non-
carriers (P-value for the full genotypic model = 1.6 10-20, Table 2).
None of the other SSS associations deviated from the additive model
(P > 0.05). KRT8 encodes the intermediate filament keratin 8 (K8,
Supplementary material online, Figure S3) which is widely expressed,
including in the heart,55 and we detected its expression (52.1± 30.2
transcripts per million) in our cardiac samples from right atria
(n = 169, Supplementary material online, Methods). Neither
p.Gly62Cys nor two correlated variants (R2 > 0.6) associated with
the expression of KRT8 or nearby genes (1 Mb) in our cardiac sam-
ples (Supplementary material online, Table S7) or in GTEx.55
About 1 in 5000 individuals from the four European populations in
























































































































































































































































































































































































































































































































































































































































































































































































































































































.Hardy–Weinberg equilibrium (P¼ 0.071–0.82). To evaluate the pene-
trance of SSS among homozygous carriers of p.Gly62Cys, we analysed
the two largest SSS datasets in the study, deCODE and CHB-CVS/
DBDS. Considering that SSS is a late onset disease, the observed
penetrance is relatively high although incomplete (Figure 2). Eight out
of 36 genotyped Icelandic homozygotes (aged 23–88 years, mean
59.9) had SSS (Supplementary material online, Table S8) and 10 out of
79 homozygotes (aged 27–103 years, mean 62.1) in CHB-CVS/DBDS.
Homozygotes were not significantly younger at SSS diagnosis than het-
erozygotes or non-carriers (P = 0.53 in deCODE and P = 0.26 in
CHB-CVS/DBDS, Supplementary material online, Table S9).
Diverse associations of sick sinus
syndrome variants with other
phenotypes
We tested the associations of the SSS variants with other phenotypes
in deCODE, CHB-CVS/DBDS, and the UK Biobank datasets
(Supplementary material online, Tables S10–S14). In addition to SSS,
p.Gly62Cys in KRT8 associated with pacemaker implantation (OR
heterozygotes = 1.28, 95% CI = 1.13–1.45, OR homozygotes = 9.17,
95% CI = 2.89–29.09, P = 1.9 10-8). The variant did not associate
with other arrhythmias or cardiovascular diseases, with electrolyte
or hormonal disturbances that are linked to the development of SSS
(potassium, calcium, thyroid stimulating hormone)57 or with the sug-
gested consequence of p.Gly62Cys in candidate gene studies58 (pan-
creatitis/lipase, liver disease, Bonferroni-adjusted significance
threshold of P = 0.05/23 = 0.0022, Supplementary material online,
Tables S10 and S11). Furthermore, p.Gly62Cys did not associate with
any of the 122 ECG parameters (N up to 72 825, Supplementary ma-
terial online, Table S13).
The associations of SSS variants with AF varied. p.Gly62Cys in
KRT8 (Supplementary material online, Tables S10 and S11) and the
missense variants in TTN/CCDC141 (Supplementary material online,
Table S12) did not associate with the risk of AF, applying a
Bonferroni-corrected significance threshold of P< 0.05/14 = 0.0036.
The TTN/CCDC141 variants are located within 300 kbp from previ-
ously reported AF variants41 and are independent of them (R2 < 0.2,
Supplementary material online, Figure S4). The other four SSS loci
have been reported to affect AF but their pattern of association with
the two phenotypes differ. p.Arg721Trp in MYH623 associates stron-
ger with SSS than AF but the reverse applies to variants at PITX2. At
ZFHX3, the effects on AF and SSS are comparable.41,50,51,59,60
p.Val1073Ala in SCN10A is one of the top AF variants at this locus
(Supplementary material online, Figure S5), but the allele that
Figure 1 Regional plot of the KRT8 locus on chromosome 12q13. The plot depicts association results (P-values) with SSS (N = 6189) in a meta-ana-
lysis with data from deCODE, the CHB-CVS/DBDS, and the UK Biobank. The y-axis shows the -log10 P-value and x-axis shows the genomic position
(hg38). The lead variant of the signal (p.Gly62Cys) is labelled as a diamond and coloured purple. Other variants are coloured according to correlation
(R2) with the lead variant in the deCODE data. The plot includes variants common to the three datasets as well as variants specific to the Icelandic
deCODE data.































































































increases the risk of SSS protects against AF (Supplementary material
online, Table S12).53,61
All the SSS variants increased the risk of pacemaker implantation
(Supplementary material online, Tables S10–S12), as expected since
SSS is the most common reason for this procedure. We have previ-
ously described in detail the associations of p.Arg721Trp in MYH6
with coarctation of the aorta, other congenital malformations of the
heart, aortic valve stenosis, and heart failure23,62,63 (Supplementary
material online, Table S12). We note that p.Glu382Asp in CCDC141
associated with both second- and third-degree atrioventricular block
(AVB)52 and the association with third-degree AVB was genome-
wide significant (P = 1.3 10-14, OR = 1.27, 95% CI = 1.20–1.35) and
more significant than the SSS association. Another notable associ-
ation is that of the PITX2 variant with heart failure (Supplementary
material online, Table S12) as recently reported in a GWAS of
heart failure.47 None of the SSS variants associated with chrono-
tropic response to exercise (Supplementary material online, Tables
S15 and S16) in our dataset. However, the SCN10A and CCDC141
loci have been reported to associate with heart rate profile during
exercise in larger studies of UK Biobank data.64,65
Genetically predicted atrial fibrillation
and lower heart rate associate with sick
sinus syndrome
PGSs are powerful tools for detecting associations between pheno-
types.38 We generated PGSs for 17 exposure phenotypes using sum-
mary statistics from the largest available GWASs (Supplementary
material online, Table S2) and tested them for association with SSS in
deCODE data. Eight PGSs, for AF, heart rate, coronary artery disease
(CAD), height, QRS duration, PR interval, ischaemic stroke, and heart
failure, associated with SSS while those for BMI, type 2 diabetes
(T2D), non-HDL cholesterol, HDL cholesterol, triglycerides, and
hypertension/blood pressure traits did not (Bonferroni-adjusted sig-
nificance threshold of P = 0.05/17 = 0.0029, Supplementary material
online, Table S17). The PGS for heart rate was the only one to in-
versely associate with SSS risk.
We then performed Mendelian randomization to determine the
causality of the associations between the eight exposures and SSS,
using genome-wide significant SNPs from GWAS of the exposure
phenotypes as instruments (see Methods). Genetic predisposition to
AF and genetically determined heart rate and height associated with
the risk of SSS but the height association did not remain
after accounting for AF in a multivariate analysis (Figures 3 and 4A
and B).66–68 With few exceptions, the effects of AF variants on SSS
are proportional to their effects on AF (P = 7.8 10-14, Figure 4A and
Supplementary material online, Figure S6A). The greatest deviation
from the expected SSS effect was for the association at SCN10A
(tagged by rs6790693, OR for AF = 1.06, OR for SSS = 0.89,
Supplementary material online, Figure S6A). Mendelian randomization
did not support causality for CAD, ischaemic stroke, heart failure, PR


























































































































































































































































































































































































































































































































































































































































































































































































































Traditionally, SSS has been considered as a collection of conditions
with a variety of causes, intrinsic and extrinsic to the SA node.69
In line with this notion, we identified sequence variants associating
with SSS at six loci implicating several distinct pathways in SSS devel-
opment. One of the SSS associations is novel, with a low-frequency
missense variant, p.Gly62Cys in KRT8. One is with the reported
p.Arg721Trp in MYH6,16 and four confirm loci previously implicated
in SSS secondarily to AF, at PITX2,50 and ZFHX3,51 or ECG traits, at
SCN10A53 and TTN/CCDC141.52 The leading variants at four of the
SSS loci are missense.
KRT8 encodes K8, a cytoskeletal intermediate filament protein
widely expressed, including in skeletal muscle and the heart.55
Historically, keratins have been described as epithelial-specific inter-
mediate filaments70 and mutations affecting keratin function have al-
most exclusively been associated with diseases of the skin and other
epithelial tissues.71,72 The association of p.Gly62Cys in KRT8 with SSS
described here supports the notion of a role for K8 in the human
heart, as previously suggested by animal studies.73–76 Experiments
have revealed loss-of-function effects of p.Gly62Cys, that is located in
the head domain of K8 (Supplementary material online, Figure
S3).77,78 Glycine at position 62 is a conserved amino acid (GERP79
score 1.73) and the variant introduces cysteine into a protein other-
wise devoid of cysteine residues. This interrupts intermediate fila-
ment assembly in vitro77 and prevents K8 from serving as a phosphate
‘sponge’ for stress-activated kinases that mediate apoptosis.78 Thus,
the variant could increase the risk of SSS either by affecting the struc-
tural or cardioprotective role of K8.77,78
In addition to p.Gly62Cys in KRT8, lead variants at two other SSS
loci are missense variants in genes encoding structural components
of the heart. MYH6 encodes the alpha-myosin heavy chain (aMHC)
and TTN encodes the giant protein titin, both of which are key com-
ponents of the sarcomere.80,81 Since the identification of MYH6 in
Figure 2 Cumulative incidence curves for SSS age of onset based on KRT8 p.Gly62Cys genotype (A) in deCODE and (B) in CHB-CVS/DBDS.
Aalen–Johansen estimator was used, treating death as a competing risk.56 Age of onset was determined by the first registered ICD diagnosis of SSS
available to us and thus represents an upper range (Supplementary material online, Methods).
Figure 3 Forest plot showing causal effect estimates from a
Mendelian randomization analysis of putative risk factors on SSS.
We regressed published effects of SNPs on the respective exposure
phenotype against their SSS effects in deCODE, CHB-CVS/DBDS,
and the UK Biobank. The causal estimates are the slopes from the
regression lines where a one unit change in the exposure pheno-
types equals a one standard deviation change for quantitative traits
and an odds ratio of 2.7 for binary exposure phenotypes. The forest
plot shows the causal estimates, 95% confidence intervals, and cor-
responding P-values from the Mendelian randomization analysis.
*For height, the result from a multivariate analysis accounting for AF
effects is shown.




















































..the first GWAS of SSS,16 structural components of cardiomyocytes
have increasingly been implicated in atrioventricular conduction and
arrhythmias, in particular AF.23,41,82,83 However, the variants at KRT8,
MYH6 and TTN do not mediate their risk through AF because they ei-
ther do not associate with AF (KRT8 and TTN) or have a stronger ef-
fect on SSS risk (MYH6).
K8, aMHC, and titin have a common role in cardiac adaptive
responses to stress which may be of relevance to their association
with SSS. aMHC allows greater economy in force generation than
the homologous beta chain and a shift in their relative expression
plays a major role in regulating myocardial contractile activity.84,85
Likewise, the isoform switch of titin alters ventricular filling81,86 and
K8 is upregulated under stress to maintain structural integrity.76 The
expression of all three genes is modified in human heart failure.76,84,87
Thus, whether or not the SSS variants in KRT8, MYH6 and TTN direct-
ly affect the SA node, it is possible that they could contribute to inad-
equate cardiac output and symptom development in SSS by
interrupting adaptive increase in stroke volume.
The SSS variants at PITX2 and ZFHX3 point to genes encoding
transcription factors.88,89 They likely mediate their effects on SSS
through AF since these have consistently been the strongest AF loci
in GWAS.42,50,51 Conversely, p.Val1073Ala in SCN10A has opposite
effects on the two arrhythmias. The allele that increases the risk of
SSS protects against AF.53,61 It also prolongs the PR interval53,54,61
and duration of the QRS complex.52,54 SCN10A encodes the neuron-
al sodium channel isoform Nav1.8. A plausible mechanism behind the
unique phenotypic effects of p.Val1073Ala involves Nav1.8s role in
the way in which the autonomic nervous system affects the heart.90–
92 In support of this, animal studies have shown that blockade of
Nav1.8 in intracardiac autonomic neurons in the ganglionated plexi
(GP) suppresses AF inducibility.90,91 The same applies to GP ablation
in patients with AF.93–95 However, GP ablation is controversial due
to observed adverse events,96–98 including development of SSS and
pacemaker implantation.99 The opposite effects of p.Val1073Ala on
SSS and AF risk support concerns that GP ablation for AF treatment
may cause SSS and links this adverse effect to Nav1.8 function
specifically.
Our genetic analyses shed light on pathways contributing to the
development of SSS and the role of risk factors. In particular, they
provide insight into the intricate and debated relationship between
SSS and AF.22 Our Mendelian randomization analysis reveals a strong
association between genetic predisposition for AF and risk of SSS.
This is consistent with our previous report23 and likely reflects caus-
ality. Pacing-induced AF has been shown to impair SA node function
in dogs100 and AF causes regional atrial substrate changes around the
SA node in humans.27 Pathobiological pathways common to AF and
SSS, such as inflammation, interstitial atrial fibrosis, and alterations in
intracellular Ca2þ dynamics, may also contribute to this trend.22,26,101
Importantly, our results also show that SSS does not only occur as
a consequence of AF or pathways common to AF. This is evident in
the case of SSS variants at KRT8 and TTN/CCDC141 that do not asso-
ciate with the risk of AF in a large dataset. p.Gly62Cys in KRT8 is the
only SSS variant that does not associate with other arrhythmias, ECG
traits, or cardiovascular diseases in our dataset. Thus, this variant in
particular may point to a mechanism that is specific to SSS develop-
ment. We observe a genome-wide significant association of
p.Glu382Asp in CCDC141 with third-degree AVB, the first one
reported for complete heart block. Therefore, this locus points to a
Figure 4 Visualization of significant associations from Mendelian randomization analysis. Effects of published variants on two phenotypes plotted
against their effects on SSS in deCODE, CHB-CVS/DBDS, and the UK Biobank (y-axes, N = 6189). The x-axes depict (A) published AF effects41,42 and
(B) heart rate effects in UK Biobank.43 The equations for the regression lines are shown and the coefficients of determination (R2).































































































mechanism linking the functions of the AV and SA nodes and does
not mediate the risk of SSS as a consequence of AF. The complexity
of the relationship between SSS and AF is further evident by the op-
posite effects of the SCN10A locus on the two arrhythmias. Finally,
since SSS variants do not consistently associate with AF, our data do
not suggest a strong causal role for SSS in the development of AF.
Heart rate variants associate inversely with SSS, consistent with
epidemiological observation,17 potentially because bradycardia is an
integral part of the SSS diagnosis. However, lower heart rate could
also represent a direct marker of biological processes affecting SSS,
such as fibrosis or altered autonomic neural input. Finally, lack of
associations with powerful PGSs based on large datasets serves as
convincing evidence against causality.25 In particular, this applies to
BMI, cholesterol, triglycerides, and T2D.
Several of our findings have direct clinical implications. In particular,
the causal role of AF in SSS development emphasizes the need for
heightened awareness of potential SSS among patients with AF, espe-
cially those with unspecific symptoms. Furthermore, the strong asso-
ciation of the SSS variant p.Glu382Asp in CCDC141 with AVB
encourages consideration of dual chamber pacemaker implantation
in SSS patients carrying this variant. Lastly, the SCN10A locus points
to SSS as a potential adverse effect of GP ablation therapy for AF.
The major strength of the study is the large SSS sample set and ex-
tensive phenotypic and genotypic data for the same datasets.
Different proportions of comorbidities and drug use in SSS cases and
controls could constitute confounding; however, the consistent asso-
ciations of SSS variants with both SSS and pacemaker implantation
across cohorts support their true effect on cardiac conduction.
Furthermore, if a specific comorbidity would explain one of the SSS
associations, this would be evident by a stronger effect on that
phenotype. The strength of Mendelian randomization in determining
causality includes less concern for confounding and reverse causation
than in observational studies since sequence variants associated with
the exposure (e.g. AF) are randomized during meiosis and this pro-
cess is unaffected by the presence of the outcome (SSS) later in life.24
For heart failure, a limitation of the Mendelian randomization analysis
is that variants identified in GWAS are not ideal instruments because
of their association with potential confounders (e.g. AF, CAD, and
BMI).47
Conclusion
In this large genetic study, we found six SSS loci, some of which also
associate with other arrhythmias and cardiac electrical function. One
of the associations is with a missense variant in the intermediate fila-
ment gene KRT8 that confers high risk of SSS among homozygous
carriers. Mendelian randomization analysis suggests that AF and
lower heart rate are directly involved in SSS development. PGS ana-
lysis provides convincing evidence against causality for BMI, choles-
terol, triglycerides, and T2D. On the other hand, the data also show
that SSS can result from perturbation of pathways unrelated to AF. In
particular, p.Gly62Cys at KRT8 does not associate with any other car-
diovascular traits and points to a mechanism that is specific to SSS
development.
Supplementary material
Supplementary material is available at European Heart Journal online.
Data availability
The Icelandic population WGS data has been deposited at the
European Variant Archive under accession code PRJEB15197. We
declare that the data supporting the findings of this study are available
within the article, its Supplementary material online and upon reason-
able request. The genome-wide association scan summary data will
be made available at http://www.decode.com/summarydata.
Acknowledgements
We thank all the study subjects for their valuable participation as
well as our colleagues that contributed to data collection, sample
handling, and genotyping.
Funding
This work was partly supported by NordForsk through the funding to
PM Heart, project number 90580, the Innovation Fund Denmark (IFD)
under File No. 8114-00033B and the Technology Development Fund,
Iceland, project number 90580.
Conflict of interest: The following authors affiliated with deCODE
genetics/Amgen, Inc., are employed by the company: R.B.T., G.S., H.M.A.,
S.B., L.S., E.V.I., G.H.H., J.K.S., A.O., V.T., K.E.H., O.B.D., S.R., S.J., G.T.,
M.L.F., G.T., G.L.N., A.H., S.G., P.S., I.J., D.O.A., U.T., D.F.G., H.H., and K.S..
D.W. received grants from Novo Nordisk Foundation during the conduct
of the study. S.B. is a board member for Proscion A/S and Intomics A/S.
References
1. Mond HG, Proclemer A. The 11th world survey of cardiac pacing and implant-
able cardioverter-defibrillators: calendar year 2009—a World Society of
Arrhythmia’s project. Pacing Clin Electrophysiol 2011;34:1013–1027.
2. Ferrer MI. The sick sinus syndrome. Circulation 1973;47:635–641.
3. Fuster V, Harrington RA, Narula J, Eapen ZJ, Hurst’s the Heart. 14th ed. New
York: McGraw-Hill Education; 2017.
4. Brignole M, Auricchio A, Baron-Esquivias G, Bordachar P, Boriani G, Breithardt
OA, Cleland J, Deharo JC, Delgado V, Elliott PM, Gorenek B, Israel CW,
Leclercq C, Linde C, Mont L, Padeletti L, Sutton R, Vardas PE. 2013 ESC guide-
lines on cardiac pacing and cardiac resynchronization therapy: the task force on
cardiac pacing and resynchronization therapy of the European Society of
Cardiology (ESC). Developed in collaboration with the European Heart
Rhythm Association (EHRA). Europace 2013;15:1070–1118.
5. Le Scouarnec S, Bhasin N, Vieyres C, Hund TJ, Cunha SR, Koval O, Marionneau
C, Chen B, Wu Y, Demolombe S, Song LS, Le Marec H, Probst V, Schott JJ,
Anderson ME, Mohler PJ. Dysfunction in ankyrin-B-dependent ion channel and
transporter targeting causes human sinus node disease. Proc Natl Acad Sci USA
2008;105:15617–15622.
6. Zhu YB, Luo JW, Jiang F, Liu G. Genetic analysis of sick sinus syndrome in a
family harboring compound CACNA1C and TTN mutations. Mol Med Rep 2018;
17:7073–7080.
7. Benson DW, Wang DW, Dyment M, Knilans TK, Fish FA, Strieper MJ, Rhodes
TH, George AL. Jr., Congenital sick sinus syndrome caused by recessive muta-
tions in the cardiac sodium channel gene (SCN5A). J Clin Investig 2003;112:
1019–1028.
8. Makita N, Sasaki K, Groenewegen WA, Yokota T, Yokoshiki H, Murakami T,
Tsutsui H. Congenital atrial standstill associated with coinheritance of a novel
SCN5A mutation and connexin 40 polymorphisms. Heart Rhythm 2005;2:
1128–1134.
9. Makiyama T, Akao M, Tsuji K, Doi T, Ohno S, Takenaka K, Kobori A, Ninomiya
T, Yoshida H, Takano M, Makita N, Yanagisawa F, Higashi Y, Takeyama Y, Kita
T, Horie M. High risk for bradyarrhythmic complications in patients with
Brugada syndrome caused by SCN5A gene mutations. J Am Coll Cardiol 2005;46:
2100–2106.
10. Ishikawa T, Ohno S, Murakami T, Yoshida K, Mishima H, Fukuoka T, Kimoto H,
Sakamoto R, Ohkusa T, Aiba T, Nogami A, Sumitomo N, Shimizu W, Yoshiura
KI, Horigome H, Horie M, Makita N. Sick sinus syndrome with HCN4 mutations































































































shows early onset and frequent association with atrial fibrillation and left ven-
tricular noncompaction. Heart Rhythm 2017;14:717–724.
11. Milanesi R, Baruscotti M, Gnecchi-Ruscone T, DiFrancesco D. Familial sinus
bradycardia associated with a mutation in the cardiac pacemaker channel. N
Engl J Med 2006;354:151–157.
12. Nof E, Luria D, Brass D, Marek D, Lahat H, Reznik-Wolf H, Pras E, Dascal N,
Eldar M, Glikson M. Point mutation in the HCN4 cardiac ion channel pore
affecting synthesis, trafficking, and functional expression is associated with famil-
ial asymptomatic sinus bradycardia. Circulation 2007;116:463–470.
13. Stallmeyer B, Kuß J, Kotthoff S, Zumhagen S, Vowinkel K, Rinné S, Matschke
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Dörr M, Dudley SC, Dunn ME, Engström G, Esko T, Felix SB, Finan C, Ford I,
Ghanbari M, Ghasemi S, Giedraitis V, Giulianini F, Gottdiener JS, Gross S,
Guðbjartsson DF, Gutmann R, Haggerty CM, van der Harst P, Hyde CL,
Ingelsson E, Jukema JW, Kavousi M, Khaw K-T, Kleber ME, Køber L, Koekemoer
A, Langenberg C, Lind L, Lindgren CM, London B, Lotta LA, Lovering RC, Luan
Ja, Magnusson P, Mahajan A, Margulies KB, März W, Melander O, Mordi IR,
Morgan T, Morris AD, Morris AP, Morrison AC, Nagle MW, Nelson CP,
Niessner A, Niiranen T, O’Donoghue ML, Owens AT, Palmer CNA, Parry HM,
Perola M, Portilla-Fernandez E, Psaty BM, Regeneron Genetics C, Rice KM,
Ridker PM, Romaine SPR, Rotter JI, Salo P, Salomaa V, van Setten J, Shalaby AA,
Smelser DT, Smith NL, Stender S, Stott DJ, Svensson P, Tammesoo M-L, Taylor
KD, Teder-Laving M, Teumer A, Thorgeirsson G, Thorsteinsdottir U, Torp-
Pedersen C, Trompet S, Tyl B, Uitterlinden AG, Veluchamy A, Völker U, Voors
AA, Wang X, Wareham NJ, Waterworth D, Weeke PE, Weiss R, Wiggins KL,
Xing H, Yerges-Armstrong LM, Yu B, Zannad F, Zhao JH, Hemingway H,
Samani NJ, McMurray JJV, Yang J, Visscher PM, Newton-Cheh C, Malarstig A,
Holm H, Lubitz SA, Sattar N, Holmes MV, Cappola TP, Asselbergs FW,
Hingorani AD, Kuchenbaecker K, Ellinor PT, Lang CC, Stefansson K, Smith JG,
Vasan RS, Swerdlow DI, Lumbers RT. Genome-wide association and Mendelian
randomisation analysis provide insights into the pathogenesis of heart failure.
Nat Commun 2020;11:163–163.
48. Ntalla I, Weng LC, Cartwright JH, Hall AW, Sveinbjornsson G, Tucker NR,
Choi SH, Chaffin MD, Roselli C, Barnes MR, Mifsud B, Warren HR, Hayward C,
Marten J, Cranley JJ, Concas MP, Gasparini P, Boutin T, Kolcic I, Polasek O,
Rudan I, Araujo NM, Lima-Costa MF, Ribeiro ALP, Souza RP, Tarazona-Santos
E, Giedraitis V, Ingelsson E, Mahajan A, Morris AP, Del Greco MF, Foco L,
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